Replies to post #508464 on Billionaire Boys Club Member Forum (BBCMF)

[02opida]

all 67 counties in Pa in lock down now

[riskon]

started w/ ice coffee; now hot coffee!

[mick]

excerpt,target price of $55.00,By Kiel Taylor -March 30, 2020,Checking the True Picture for Taronis Technologies, Inc. (TRNX)
By Kiel Taylor -March 30, 2020

https://uspostnews.com/2020/03/30/checking-the-true-picture-for-taronis-technologies-inc-trnx/


[-chart]uspostnews.com/wp-content/uploads/2019/03/2-696x490.jpg[/chart]

On Friday, shares of Taronis Technologies, Inc. (NASDAQ:TRNX) marked $0.15 per share versus a previous $0.17 closing price. With having a -11.49% loss, an insight into the fundamental values of Taronis Technologies, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts.

TRNX showed a fall of -82.93% within its YTD performance,
with highs and lows between $0.14 – $5.25 during the period of 52 weeks, compared to the simple moving average of -89.10% in the period of the last 200 days.

Taronis Technologies, Inc. (TRNX) Analysis
The present dividend yield for TRNX owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period.

In addition, the growth of sales from quarter to quarter is recording 103.80%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of Taronis Technologies, Inc.
(TRNX) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance.

In this case, you want to make sure that the return on the present equity of -104.90% is enough for you to make a profit out of your investment.

You may also count in the quick ratio of the company, currently set at 0.70 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator,
while TRNX is currently recording an average of 3.86M in volumes.

The volatility of the stock on monthly basis is set at 28.52%,
while the weekly volatility levels are marked at 24.18%with -6.12% of loss in the last seven days.

Additionally, long-term investors are predicting the
target price of $55.00,

indicating growth from the present price of $0.15, which can represent yet another valuable research and analysis points that can help you decide whether to invest in TRNX or pass.

What to Look for When Analyzing Taronis Technologies, Inc. Shares?

Taronis Technologies, Inc. (TRNX) is based in the Netherlands and it represents one of the well-known company operating with Basic Materials sector.

If you wish to compare TRNX shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Taronis Technologies, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations.

The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -7.20 is supported by the yearly ESP growth of .

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors.

In that spirit, the present ownership of stocks inside the company is set at 7.00%, which can provide you with an insight of how involved executives are in owning shares of the company.

In oppose to the executives’ share, the institutional ownership counts 1.80% of shares, carrying an equal significance as an indicator of value,
as the presence of large investors may signal a strong company.

Are Institutional Investors Increasing Stakes in TRNX Shares?
It appears that more than several institutional investors and hedge funds decided to increase stakes in TRNX in the recent period. That is how The Vanguard Group, Inc. now has an increase position in TRNX by 21.55% in the first quarter, owning 707711 shares of TRNX stocks, with the value of $214436 after the purchase of an additional 125,475 shares during the last quarter.

In the meanwhile, OxFORD Asset Management LLP also increased their
stake in TRNX shares changed
— in the first quarter,
which means that the company now owns 162962 shares of company,
all valued at $49377 after the acquisition of additional 162,962 shares during the last quarter.

Geode Capital Management LLC acquired a new position in Taronis Technologies, Inc. during the first quarter,
with the value of $46129, and

Northern Trust Investments, Inc. increased their stake in the company’s shares by 80.84% in the first quarter,
now owning 14,912 shares valued at $10107 after the acquisition of the additional 33358 shares during the last quarter.

In the end, BlackRock Fund Advisors increased their position by 29.30% during the first quarter,
now owning 19738 TRNX shares, now holding the value of $5981 in TRNX with the purchase of the additional 19,738 shares during the period
of the last quarter.

At the present, 1.80% of TRNX shares are in the ownership of institutional investors.

TAGSInc.NASDAQ:TRNX Taronis Technologies TRNX TRNX stock TRNX stock price

[mick]

The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation
7:57 am ET April 2, 2020 (Benzinga) Print
Here's a roundup of top developments in the biotech space over the last 24 hours.

On a day when the three major averages shed over 4% in reaction to bleak forecasts concerning the COVID-19 pandemic's impact, none of the Nasdaq- or NYSE-listed biotech stocks hit 52-week highs or lows.

Stocks In Focus InVitae Withdraws FY20 Guidance Due To Pandemic, Plans Offering
NVTA
InVitae Corp (NYSE: NVTA), a medical genetics company, pre-announced first-quarter results and said it expects revenue of more than $63 million, up 55% year-over-year, billable tests of 147,000, up 65%, and non-GAAP cash burn of less than $100 million.
Analysts expect revenue of $60.3 million.

NVTA
Citing the unknown duration and extent of COVID-19's impact on its business and the health care system in general, the company said it is withdrawing its guidance for 2020.

Separately, the company announced an underwritten public offering of 17.78 million shares priced at $9 per share. All the shares are being sold by the company. The company expects the offering to close April 6 and to raise gross proceeds of about $16 million.

The stock was down 11.96% at $10.31 in Thursday's premarket session.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

NVS
Novartis Terminates Agreement To Sell Sandoz US Assets To Aurobindo
NVS
Novartis AG (NYSE: NVS) said it has mutually agreed with Aurobindo Pharma to terminate a previously announced deal to sell the Sandoz U.S. generic oral solids and dermatology businesses to Aurobindo. The decision follows a lack of FTC approval for the transaction within anticipated timelines.
NVS
Novartis shares were adding 1.57% to $82.20 in premarket trading Thursday.

NVRO
Nevro Forecasts Q1 Revenue Shortfall, Withdraws 2020 Guidance
NVRO
Nevro Corp (NYSE: NVRO) announced preliminary unaudited worldwide revenue for the first quarter of $86.4 million to $86.9 million, up from $82.1 million a year ago. This compares to the $94.96-million consensus estimate. The company attributed the potential shortfall to a rapid deceleration in March due to COVID-19 shelter-in-place policies and restrictions on elective surgical procedures.

The company also withdrew its 2020 guidance issued in late February due to the rapidly evolving environment and continued uncertainties related to COVID-19.

Separately, the company announced a public offering of 1.625 million shares of common stock and $165 million in aggregate principal amount of convertible senior notes due 2025.

The stock fell 3.86% to $86 in after-hours trading.

OpGen Closes On Curetis Purchase
OPGN
OpGen Inc (NASDAQ: OPGN) announced the consummation of its proposed acquisition of Dutch molecular diagnostics company Curetis N.V. OpGen shares paid as consideration for the sale will be distributed to Curetis, which will be dissolved and delisted from the Euronext exchange.
OPGN
OpGen shares were trading 5.44% higher at $2.52 in Thursday's premarket session.

See also: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty

EIGR
Eiger's HDV Study To Be Delayed, Company To Support Studies Of Peginterferon Lambda In COVID-19

EIGR
Issuing an update on clinical development activity and business operations, Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) said it has taken appropriate steps to ensure the safety of patients and integrity of the HDV Phase 3 D-LIVR trial. The trial is evaluating lonafarnib and ritonavir with or without PEGylated interferon-alfa-2a in patients with chronic hepatitis D virus infection.

It now expects the COVID-19 pandemic to lead to the shifting of the completion of enrollment in the study to 2021.

The company also said it has begun supporting multiple investigator-sponsored studies of peginterferon lambda in COVID-19.

"These studies will assess a 180 mcg, once-weekly, subcutaneous dose of Lambda, and will enroll at academic centers across the U.S., as well as international sites," the company said.

The shares advanced 6.27% to $6.27 in after-hours trading.

AFMD
Affimed's Lead Drug Gets Orphan Drug Designation In T-Cell Lymphoma

AFMD
Affimed NV (NASDAQ: AFMD) said the FDA has granted orphan drug designation to AFM13, its lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.
AFMD
Affimed shares were up 6.92% to $1.70 in the premarket session.

BCRX
BioCryst Names Anthony Doyle As CFO

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the appointment of Anthony Doyle as CFO. Doyle previously served as a global contract research organization's CFO.
BCRX
In premarket trading Thursday, BioCryst shares were adding 0.26% to $1.90.

BSX
Boston Scientific Lowers Q1 Revenue Guidance Due To COVID-19 Impact

BSX
Boston Scientific Corporation (NYSE: BSX) lowered its first-quarter revenue growth guidance to flat to slightly up from its previous estimate for 10-12% growth. The company attributed the predicament to a significant decline in procedural volumes in March due to COVID-19 impact.

HGEN
Humanigen's Lenzilumab Gets FDA Nod For Compassionate Use In COVID-19 Patients

HGEN
Humanigen Inc (OTC: HGEN) said the FDA approved the administration of its lenzilumab for COVID-19 patients under individual patient emergency IND applications to patients under its compassionate use program.

The company said it is advancing plans to conduct a multi-center,
Phase 3 study of lenzilumab for the prevention of acute respiratory distress syndrome, ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 infection.

APLT
Applied Therapeutics Opens IND With FDA For AT-001 To Treat COVID-19-Related Lung Inflammation, Cardiomyopathy

APLT
Applied Therapeutics Inc (NASDAQ: APLT) said it has opened an INDA with the FDA for AT-001 to treat acute lung inflammation and cardiomyopathy in critical COVID-19 patients. The company noted that multiple AT-001 investigator-initiated trials are now underway to address these two issues.

VIR ALNY
Vir, Alnylam Expand Existing Collaboration To Include Additional Targets In COVID-19 Treatment

VIR ALNY
Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion of their existing collaboration for RNAi therapeutics for infectious diseases.

The expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry.
VIR
Vir shares were gaining 2.45% to $30.50 in premarket trading Thursday.

Related Link: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.